Levels of serum Krebs von den Lungen-6 (KL-6) can serve as a useful noninvasive diagnostic biomarker for improving the certainty of a diagnosis of idiopathic pulmonary fibrosis (IPF) vs other forms of interstitial lung disease (ILD) and to help evaluate disease severity. However, the use of KL-6 alone is insufficient for assessing disease prognosis. These were among the results of a retrospective cohort study published in The Clinical Respiratory Journal.

The investigators sought to evaluate the diagnostic value of serum KL-6 concentrations and whether the expression value of KL-6 could be indicative of disease severity in patients with IPF. In order the address this objective, they needed to explore whether certain parameters, such as patients’ physical characteristics and other clinical conditions, could impact their baseline KL-6 levels.

The study included 100 patients diagnosed with IPF between January 2007 and October 2014 who were admitted to the Department of Pulmonary and Critical Care Medicine at Beijing Chao-Yang Hospital, Capital Medical University, in Beijing, China. Further, 127 patients with other forms of ILD — that is, 86 with cryptogenic organizing pneumonia and 41 with sarcoidosis — were evaluated as well. Additionally, 298 healthy controls who were the same age (±5 years) as the patients selected for the study also were evaluated. The controls, all of whom were selected at the time of a health examination, had no history of any lung disease and had normal chest x-rays.

Continue Reading

At diagnosis of IPF and ILD, clinical data and bronchoalveolar lavage fluid (BALF) samples were obtained. Clinical data included epidemiology information, physical examinations, pulmonary function tests, high-resolution computed tomography (HRCT), and serologic laboratory tests.

More patients in the IPF group than in the other 2 groups were either smokers or ex-smokers. The smoking index, which is indicated by pack-years, was also higher among those in the IPF arm. Patients in the IPF group were older than those in the other ILD groups.

Results of the study showed that KL-6 concentrations were significantly increased in patients with IPF vs in study participants with other types of ILD and in the healthy controls group (1344±140.4 U/mL, 850.7±125.4 U/mL, and 248.6±7.406 U/mL, respectively). The KL-6 cut-off value was 540.5 U/mL, with a sensitivity of 81.98% and a specificity of 95.97%. The likelihood ratio was 20.36 (95% CI, 0.90-0.97; P <.0001), with all of these data demonstrating that KL-6 performs well as a valuable diagnostic marker in patients with IPF.

KL-6 concentrations in serum were significantly higher than those in BALF samples (1344±140.4 U/mL vs 245.2±49.1 U/mL, respectively; P <.001). A positive association, however, was observed between KL-6 levels in serum and in BALF (r = 0.4446; P< .001), with the lower KL-6 level in BALF due most likely to the lower level of total protein concentration. Although serum KL-6 is a stable biomarker that is not affected by lung infection and smoking status, those in the IPF arm with antinuclear antibodies demonstrated higher KL-6 levels. KL-6 levels, along with poor pulmonary function and high radiologic fibrosis scores, are indicative of the severity of an individual’s IPF, but not of poor survival.

The researchers concluded that although the current findings present a comprehensive overview of initial KL-6 concentrations in the diagnosis and evaluation of IPF, the use of KL-6 was insufficient for assessing disease prognosis.


Jiang D, Xiao H, Dong R, et al. Krebs von den Lungen-6 levels in untreated idiopathic pulmonary fibrosis. Clin Respir J. Published online January 26, 2022. doi:10.1111/crj.13475